Mataró, Barcelona, Spain, and Düsseldorf, Germany, 09 September 2026 - Minoryx Therapeutics and Neuraxpharm Group (Neuraxpharm), announce that the last patient has been enrolled in the global Phase 3 clinical...
Arthur Klausner to participate in the panel "Alternatives for Creating Value in a challenging time" at NASDAQ Healthcare Industry Forum in New York City
News | 12. 08. 2008
